BRAF and neoplasm: In terms of PFS, a detrimental effect of anti-EGFR antibodies in patients with caecal RAS/BRAF wild-type mCRC was observed (multivariate Cox regression: HR 2.50), whereas no significant differences in all other segments were evident with rather neutral effects evolving with more distal primary tumor location.